Drug discovery and development firm Immupharma on Thursday revealed that its pre-clinical work on P140, a peptide being developed as a Lupus treatment, may have other potential indications.
Drug discovery and development company ImmuPharma saw losses widen in its last trading year, but fresh analysis of results from its pivotal Phase III trial on its Lupus treatment has given both the firm and its investors some reason to be optimistic.
A recent Phase III study undertaken by drug discovery and development company ImmuPharma demonstrated a superior response rate from its lupus compound, Lupuzor, but, due to a high response rate in the placebo group, the group's superior response was unable to allow statistical significance to be reached and the trial's primary endpoint was not met.
Mitie Group: Barclays upgrades to overweight with a target price of 180p.
Specialist drug discovery and development company ImmuPharma announced on Friday that it has been informed by Simbec-Orion, the contract research organisation conducting its 'Lupuzor' pivotal Phase III trial study, that 'database lock' was expected on 6 April, with top line results announced by mid-April.
Countrywide: Berenberg upgrades to hold with a target price of 95p.
Specialist drug discovery and development company ImmuPharma announced on Wednesday that, in response to institutional demand, it has completed a fundraise totalling £10m before expenses via a placing of 6,944,445 new ordinary shares at a price of 144p per share, with new and existing investors.
Rightmove: JP Morgan upgrades to neutral with a target price of 4,168p.
Biotech company ImmuPharma said Phase III clinical trials of its Lupus treatment, Lupuzor, continued to progress on track and time, with all patients in the study having passed the nine-month stage and 116 patients completing the full 12 months.
Specialist drug discovery and development company ImmuPharma announced the completion of the sharing agreement entered into with Lanstead Capital in February 2016 on Wednesday.
Specialist drug discovery and development company ImmuPharma confirmed a further update on its lead programme for a potential breakthrough compound for lupus, Lupuzor, on Tuesday.
Specialist drug discovery and development company ImmuPharma updated the market on Friday on its "pivotal" 52-week randomised, double-blinded Phase III clinical trial of Lupuzor - its lead programme for the potential "breakthrough compound" for the life threatening autoimmune disease lupus.
Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupuzor.
Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor.
Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of Lupuzor - its lead programme for the potential breakthrough compound for Lupus - on Wednesday.
ImmuPharma's clinical expansion into the US reached a significant point on Monday, with the first dosing of patients in its Phase III trial of the in-development lupus treatment Lupuzor.
The 'blockbuster' potential of a drug in development saw ImmuPharma proposing a £7.5m fund raise on Friday.
ImmuPharma has reached a number of important milestones in the phase three clinical trial of Lupuzor.
Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus.
Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. If the Australian project is delayed, BG could suffer penalty payments for contracts agreed. In the meantime, BG has no chief executive. Fortson concluded he was with Credit Suisse on BG.